Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations Agrees To Amend 2014 Loan Facility (ALLISS)

Mon, 11th Mar 2019 18:11

LONDON (Alliance News) - Amphion Innovations PLC said Monday it has amended its loan facility first agreed in 2014 and then amended last October.

Amphion amended the loan interest rate to 10% per annum and agreed to give the lender 15% of the appreciation on 10.0 million of Amphion's shares in Motif Bio PLC, above 33 pence. The 15% appreciation will be cut to 10% if the loan is fully repaid by the end of March.

Amphion and the lender have now agreed to sell USD750,00 of Motif Bio shares with two-thirds of the proceeds being used to reduce the loan balance, which currently stands at USD4.1 million.

Going forward, the loan interest rate will remain at 10% but the lender will receive 15% of the future appreciation of 10.0 million Motif shares above 10p and also 15% of the appreciation in 10.0 million Polarean Imaging PLC shares above 18p.

The agreement will end in September 2021 or when Amphion has sold all of its shares in Motif and Polarean.

Amphion's pledge of 24.5 million Motif shares will continue to act as Amphion's security for the loan. Amphion retains its beneficial interest in all pledged shares, although it has transferred the legal title to the majority of these.

Shares in Amphion Innovations closed flat Monday at 0.38 pence each.

More News
1 Jun 2020 11:16

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Read more
5 May 2020 10:58

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Read more
5 May 2020 09:17

Motif Bio raises ?0.65m as it hunts for reverse takeover opportunity

(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.

Read more
4 May 2020 15:42

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Read more
14 Apr 2020 17:12

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Read more
19 Mar 2020 14:51

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Read more
18 Mar 2020 15:33

Motif Bio struggling to find reverse takeover opportunity

(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.

Read more
28 Jan 2020 11:31

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Read more
26 Nov 2019 18:15

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Read more
18 Nov 2019 13:50

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Read more
11 Nov 2019 09:52

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Read more
11 Nov 2019 09:40

Motif Bio reaches settlement with former clinical research organisation

(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.

Read more
25 Oct 2019 17:34

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Read more
24 Oct 2019 16:05

Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.

Read more
24 Oct 2019 12:01

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.